CliffBio
small molecule

BREYNA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

Loss of exclusivity—loss of exclusivity
CompanyMylan →See this company's full patent-cliff portfolio

Drug detail

Brand nameBREYNA
Active ingredientBUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE
Strength0.08MG/INH;0.0045MG/INH
Dosage formAEROSOL, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalMarch 2022
Marketing statusRX

More from Mylan

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BREYNA patent cliff — loss of exclusivity — | CliffBio